Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance ...
Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment 1.5% mean weight change observed with ...
The S&P 500 has enjoyed another respectable year of gains, now up just north of 15% year to date despite the bout of November volatility. As you’d imagine, the Magnificent Seven have once again ...
The S&P 500 is up over 15% year to date with the Magnificent Seven driving most gains. The Invesco S&P 500 Equal Weight ETF has been showing signs of outperformance amid the recent rebound. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback